IGC Pharma, Inc.

Day range

$0.24 – $0.26

Open

$0.25

Prev close

$0.25

Volume

322.81K

Market cap

$25.43M

Shares out

116.14M

P/E

—

P/S

19.81

P/B

4.22

P/FCF

—

ROE

-104.5%

ROA

-69.6%

Debt/Equity

0.15

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationJul 14, 2026

  On July 13, 2026, IGC Pharma, Inc. furnished an updated investor presentation (the "Investor Presentation"). A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K... The Company expects to use the Investor Presentation, in whole or in part and with modifications or supplements from time to time, in meetings and communications with investors, analysts, potential strategic partners and others, and at conferences and other business events.

• Private placementJul 6, 2026

  The Company issued 2,226,475 shares of common stock to Mr. Mukunda in exchange for the cancellation and satisfaction of $601,148 of outstanding amounts owed to him... The Company issued 2,048,378 shares of common stock to Ms. Grimaldi in exchange for the cancellation and satisfaction of $553,062 of outstanding amounts owed to her... The shares of common stock were issued in private transactions in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, as transactions by an issuer not involving any public offering.

• Credit facilityJun 8, 2026

  On June 5, 2026, IGC Pharma, Inc. entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender. The facility provides for a maximum aggregate limit of $12,000,000.

• Debt issuanceApr 20, 2026

  Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the "Note") to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027. Each VFG and FirstFire has 12% interest rate.

• Debt issuanceMar 12, 2026

  On March 5, 2026, IGC Pharma, Inc. entered into a Securities Purchase Agreement with Vanquish Funding Group Inc. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note to VFG with a total principal amount of $353,050, which includes an original issue discount of $46,050. The aggregate purchase price paid by VFG for the Note is $307,000. The Note matures on February 28, 2027.

Days to cover

1.4

Short interest

931.51K

Avg volume

648.27K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight
  positiveGlobeNewswire Inc.· Oct 22, 2026
• Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
  positiveGlobeNewswire Inc.· Aug 12, 2025
• Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
  positiveGlobeNewswire Inc.· Jul 10, 2025
• Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket
  Benzinga· Jul 6, 2023
• IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.
  GlobeNewswire Inc.· Mar 20, 2023